| ［1］ Vanden Berghe T, Linkermann A, JouanLanhouet S, et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways［J］. Nat Rev Mol Cell Biol, 2014, 15(2): 134-147. DOI: 10.1038/nrm3737.
［2］ Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincleinduced immune suppression［J］. Nature, 2016, 532(7598): 245-249. DOI: 10.1038/nature17403.
［3］ Lu B, Gong X, Wang ZQ, et al. Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation［J］. Acta Pharmacol Sin, 2017, 38(11): 15431553. DOI: 10.1038/aps.2017.112.
［4］ Seifert L, Miller G. Molecular pathways: the necrosomea target for cancer therapy［J］. Clin Cancer Res, 2017, 23(5): 1132-1136. DOI: 10.1158/1078-0432.CCR-16-0968.
［5］ Liu S, Liu H, Johnston A, et al. MLKL forms disulfide bonddependent amyloidlike polymers to induce necroptosis［J］. Proc Natl Acad Sci U S A, 2017, 114(36): E7450-E7459. DOI: 10.1073/pnas.1707531114.
［6］ Vanden Berghe T, Hassannia B, Vandenabeele P. An outline of necrosome triggers［J］. Cell Mol Life Sci, 2016, 73(1112): 2137-2152. DOI: 10.1007/s00018-016-2189-y.
［7］ Tenev T, Bianchi K, Darding M, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs［J］. Mol Cell, 2011, 43(3): 432-448. DOI: 10.1016/j.molcel.2011.06.006.
［8］ Dickens LS, Powley IR, Hughes MA, et al. The ′complexities′ of life and death: death receptor signalling platforms［J］. Exp Cell Res, 2012, 318(11): 1269-1277. DOI: 10.1016/j.yexcr.2012.04.005.
［9］ Ali M, Mocarski ES. Proteasome inhibition blocks necroptosis by attenuating death complex aggregation［J］. Cell Death Dis, 2018, 9(3): 346. DOI: 10.1038/s41419-018-0371-x.
［10］ Feoktistova M, Geserick P, Kellert B, et al. cIAPs block Ripoptosome formation, a RIP1/caspase8 containing intracellular cell death complex differentially regulated by cFLIP isoforms［J］. Mol Cell, 2011, 43(3): 449-463. DOI: 10.1016/j.molcel.2011.06.011.
［11］ Hanson B. Necroptosis: a new way of dying?［J］. Cancer Biol Ther, 2016, 17(9): 899-910. DOI: 10.1080/15384047.2016.1210732.
［12］ Su Z, Yang Z, Xie L, et al. Cancer therapy in the necroptosis era［J］. Cell Death Differ, 2016, 23(5): 748756. DOI: 10.1038/cdd.2016.8.
［13］ de Almagro MC, Goncharov T, Newton K, et al. Cellular IAP proteins and LUBAC differentially regulate necrosomeassociated RIP1 ubiquitination［J］. Cell Death Dis, 2015, 6: e1800. DOI: 10.1038/cddis.2015.158.
［14］ Imre G, Larisch S, Rajalingam K. Ripoptosome: a novel IAPregulated cell deathsignalling platform［J］. J Mol Cell Biol, 2011, 3(6): 324-326. DOI: 10.1093/jmcb/mjr034.
［15］ Schilling R, Geserick P, Leverkus M. Characterization of the ripoptosome and its components: implications for antiinflammatory and cancer therapy［J］. Methods Enzymol, 2014, 545: 83-102. DOI: 10.1016/B978-0-12-801430-1.00004-4.
［16］ McCabe KE, Bacos K, Lu D, et al. Triggering necroptosis in cisplatin and IAP antagonistresistant ovarian carcinoma［J］. Cell Death Dis, 2014, 5: e1496. DOI: 10.1038/cddis.2014.448.
［17］ Shi S, Wang Q, Xu J, et al. Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagymediated apoptosis［J］. Oncotarget, 2015, 6(3): 16401651. DOI: 10.18632/oncotarget.2746.
［18］ Selmi T, Alecci C, dell Aquila M, et al. ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting ripoptosome assembly［J］. BMC Cancer, 2015, 15: 357. DOI: 10.1186/s1288501513885.
［19］ Schroeder A, Warnken U, Roth D, et al. Targeting thioredoxin1 by dimethyl fumarate induces ripoptosomemediated cell death［J］. Sci Rep, 2017, 7: 43168. DOI: 10.1038/srep43168. |
